Shares of Dova Pharmaceuticals Inc (NASDAQ:DOVA) have earned a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that cover the company, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy rating.
Brokers have set a 12-month consensus target price of $35.67 for the company and are expecting that the company will post ($0.36) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Dova Pharmaceuticals an industry rank of 175 out of 265 based on the ratings given to related companies.
A number of equities research analysts have recently issued reports on DOVA shares. Zacks Investment Research downgraded shares of Dova Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, November 14th. BidaskClub raised shares of Dova Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, January 13th. Jefferies Group boosted their price objective on shares of Dova Pharmaceuticals to $33.00 and gave the company a “buy” rating in a research report on Tuesday, November 28th. Finally, Leerink Swann raised shares of Dova Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $32.00 price objective for the company in a research report on Tuesday, September 26th.
Dova Pharmaceuticals (NASDAQ:DOVA) last issued its quarterly earnings data on Thursday, November 9th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.08). During the same quarter in the previous year, the company earned ($0.41) EPS. sell-side analysts forecast that Dova Pharmaceuticals will post -1.51 earnings per share for the current year.
A number of institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System bought a new position in Dova Pharmaceuticals in the 3rd quarter worth $202,000. Schwab Charles Investment Management Inc. bought a new position in Dova Pharmaceuticals in the 3rd quarter worth $241,000. Laurion Capital Management LP bought a new position in Dova Pharmaceuticals in the 2nd quarter worth $223,000. Bank of New York Mellon Corp bought a new position in Dova Pharmaceuticals in the 3rd quarter worth $340,000. Finally, JPMorgan Chase & Co. bought a new position in Dova Pharmaceuticals in the 2nd quarter worth $382,000. 26.20% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: This story was first posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/3147994/dova-pharmaceuticals-inc-dova-given-consensus-recommendation-of-strong-buy-by-brokerages.html.
Dova Pharmaceuticals Company Profile
Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.